Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man

J. Marco, I. Correas, M. A. Zulueta, E. Vincent, D. H. Coy, A. M. Comaru-Schally, Andrew V Schally, M. D. Rodríguez-Arnao, A. Gómez-Pan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We have compared the effects of equimolar doses of intravenous somatostatin-28 (SS-28) and somatostatin-14 (SS-14) (250 μg and 125 μg, respectively) on the secretion of pancreatic polypeptide (PP), glucagon and insulin evoked by a protein-rich meal in normal subjects. Both peptides reduced the fasting plasma levels of these hormones and completely abolished their responses to the alimentary stimulus; in addition, they caused an early decrease of plasma glucose followed by a hyperglycemic phase. As compared to SS-14, SS-28 elicited a longer-lasting inhibition of PP and insulin secretion and displayed greater hypo- and hyperglycemic effects. A somatostatin-like component, similar to SS-28, has been identified in pancreatic extracts as well as in peripheral plasma. Thus, it might be hypothesized that this peptide plays a role in the control of pancreatic hormone release.

Original languageEnglish
Pages (from-to)363-366
Number of pages4
JournalHormone and Metabolic Research
Volume15
Issue number8
StatePublished - Oct 6 1983
Externally publishedYes

Fingerprint

Somatostatin-28
Pancreatic Polypeptide
Somatostatin
Glucagon
Insulin
Plasmas
Pancreatic Extracts
Pancreatic Hormones
Peptides
Hypoglycemic Agents
Meals
Fasting
Hormones
Glucose
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Marco, J., Correas, I., Zulueta, M. A., Vincent, E., Coy, D. H., Comaru-Schally, A. M., ... Gómez-Pan, A. (1983). Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man. Hormone and Metabolic Research, 15(8), 363-366.

Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man. / Marco, J.; Correas, I.; Zulueta, M. A.; Vincent, E.; Coy, D. H.; Comaru-Schally, A. M.; Schally, Andrew V; Rodríguez-Arnao, M. D.; Gómez-Pan, A.

In: Hormone and Metabolic Research, Vol. 15, No. 8, 06.10.1983, p. 363-366.

Research output: Contribution to journalArticle

Marco, J, Correas, I, Zulueta, MA, Vincent, E, Coy, DH, Comaru-Schally, AM, Schally, AV, Rodríguez-Arnao, MD & Gómez-Pan, A 1983, 'Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man', Hormone and Metabolic Research, vol. 15, no. 8, pp. 363-366.
Marco J, Correas I, Zulueta MA, Vincent E, Coy DH, Comaru-Schally AM et al. Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man. Hormone and Metabolic Research. 1983 Oct 6;15(8):363-366.
Marco, J. ; Correas, I. ; Zulueta, M. A. ; Vincent, E. ; Coy, D. H. ; Comaru-Schally, A. M. ; Schally, Andrew V ; Rodríguez-Arnao, M. D. ; Gómez-Pan, A. / Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man. In: Hormone and Metabolic Research. 1983 ; Vol. 15, No. 8. pp. 363-366.
@article{f38dedc8191c498c97bcbe4ba9a5452b,
title = "Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man",
abstract = "We have compared the effects of equimolar doses of intravenous somatostatin-28 (SS-28) and somatostatin-14 (SS-14) (250 μg and 125 μg, respectively) on the secretion of pancreatic polypeptide (PP), glucagon and insulin evoked by a protein-rich meal in normal subjects. Both peptides reduced the fasting plasma levels of these hormones and completely abolished their responses to the alimentary stimulus; in addition, they caused an early decrease of plasma glucose followed by a hyperglycemic phase. As compared to SS-14, SS-28 elicited a longer-lasting inhibition of PP and insulin secretion and displayed greater hypo- and hyperglycemic effects. A somatostatin-like component, similar to SS-28, has been identified in pancreatic extracts as well as in peripheral plasma. Thus, it might be hypothesized that this peptide plays a role in the control of pancreatic hormone release.",
author = "J. Marco and I. Correas and Zulueta, {M. A.} and E. Vincent and Coy, {D. H.} and Comaru-Schally, {A. M.} and Schally, {Andrew V} and Rodr{\'i}guez-Arnao, {M. D.} and A. G{\'o}mez-Pan",
year = "1983",
month = "10",
day = "6",
language = "English",
volume = "15",
pages = "363--366",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "8",

}

TY - JOUR

T1 - Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man

AU - Marco, J.

AU - Correas, I.

AU - Zulueta, M. A.

AU - Vincent, E.

AU - Coy, D. H.

AU - Comaru-Schally, A. M.

AU - Schally, Andrew V

AU - Rodríguez-Arnao, M. D.

AU - Gómez-Pan, A.

PY - 1983/10/6

Y1 - 1983/10/6

N2 - We have compared the effects of equimolar doses of intravenous somatostatin-28 (SS-28) and somatostatin-14 (SS-14) (250 μg and 125 μg, respectively) on the secretion of pancreatic polypeptide (PP), glucagon and insulin evoked by a protein-rich meal in normal subjects. Both peptides reduced the fasting plasma levels of these hormones and completely abolished their responses to the alimentary stimulus; in addition, they caused an early decrease of plasma glucose followed by a hyperglycemic phase. As compared to SS-14, SS-28 elicited a longer-lasting inhibition of PP and insulin secretion and displayed greater hypo- and hyperglycemic effects. A somatostatin-like component, similar to SS-28, has been identified in pancreatic extracts as well as in peripheral plasma. Thus, it might be hypothesized that this peptide plays a role in the control of pancreatic hormone release.

AB - We have compared the effects of equimolar doses of intravenous somatostatin-28 (SS-28) and somatostatin-14 (SS-14) (250 μg and 125 μg, respectively) on the secretion of pancreatic polypeptide (PP), glucagon and insulin evoked by a protein-rich meal in normal subjects. Both peptides reduced the fasting plasma levels of these hormones and completely abolished their responses to the alimentary stimulus; in addition, they caused an early decrease of plasma glucose followed by a hyperglycemic phase. As compared to SS-14, SS-28 elicited a longer-lasting inhibition of PP and insulin secretion and displayed greater hypo- and hyperglycemic effects. A somatostatin-like component, similar to SS-28, has been identified in pancreatic extracts as well as in peripheral plasma. Thus, it might be hypothesized that this peptide plays a role in the control of pancreatic hormone release.

UR - http://www.scopus.com/inward/record.url?scp=0020516074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020516074&partnerID=8YFLogxK

M3 - Article

C2 - 6137445

AN - SCOPUS:0020516074

VL - 15

SP - 363

EP - 366

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 8

ER -